0001596771-19-000002.txt : 20190104 0001596771-19-000002.hdr.sgml : 20190104 20190104144454 ACCESSION NUMBER: 0001596771-19-000002 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20190104 DATE AS OF CHANGE: 20190104 EFFECTIVENESS DATE: 20190104 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NEUROONE MEDICAL TECHNOLOGIES Corp CENTRAL INDEX KEY: 0001500198 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 270863354 STATE OF INCORPORATION: DE FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-329698 FILM NUMBER: 19509537 BUSINESS ADDRESS: STREET 1: 10006 LIATRIS LANE CITY: EDEN PRAIRIE STATE: MN ZIP: 55347 BUSINESS PHONE: (952) 237-7412 MAIL ADDRESS: STREET 1: 10006 LIATRIS LANE CITY: EDEN PRAIRIE STATE: MN ZIP: 55347 FORMER COMPANY: FORMER CONFORMED NAME: Original Source Entertainment, Inc. DATE OF NAME CHANGE: 20100830 D 1 primary_doc.xml X0708 D LIVE 0001500198 NEUROONE MEDICAL TECHNOLOGIES Corp 10901 Red Circle Dr. Suite 150 Minnetonka MN MINNESOTA 55343 (952) 237-7412 DELAWARE Original Source Entertainment, Inc. Corporation true David A. Rosa 10901 Red Circle Dr. Suite 150 Minnetonka MN MINNESOTA 55343 Executive Officer Director Thomas Bachinski 19059 Orchard Trail Lakeville MN MINNESOTA 55044 Executive Officer Mark Christianson 10901 Red Circle Dr. Suite 150 Minnetonka MN MINNESOTA 55343 Executive Officer Paul Buckman 10901 Red Circle Dr. Suite 150 Minnetonka MN MINNESOTA 55343 Director Suraj Kalia 10901 Red Circle Dr. Suite 150 Minnetonka MN MINNESOTA 55343 Director Jeffrey S. Mathiesen 10901 Red Circle Dr. Suite 150 Minnetonka MN MINNESOTA 55343 Director Biotechnology Decline to Disclose 06b false 2018-12-28 false true true true false 0 Paulson Investment Company 5670 None None 2141 W. North Ave 2nd Floor Chicago IL ILLINOIS 60647 All States false 10000000 400000 9600000 false 3 1200000 true 0 In addition to a cash commission of 12% of the gross proceeds from the offering, the brokers will receive warrants to purchase an amount of common stock equal to 10% of the total amount of shares sold in the offering. 823140 true The proceeds of this private placement, along with proceeds from other financings, may be used to pay certain executive officers. false NEUROONE MEDICAL TECHNOLOGIES Corp /s/ David A. Rosa David A. Rosa CEO 2019-01-04